Search Result
Results for "
NSPs
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-D0893
-
|
Fluorescent Dye
|
Others
|
NSP-SA-NHS is an acridinium ester that can be used for chemiluminescent immunoassay. A rapid and sensitive chemiluminescent immunoassay of Bisphenol A (BPA) with NSP-SA-NHS-labeled has been developed .
|
-
-
- HY-146584
-
|
Cathepsin
|
Inflammation/Immunology
|
Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally active Cathepsin C inhibitor with IC50s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity .
|
-
-
- HY-150622
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
|
-
-
- HY-150062
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
|
-
-
- HY-124654
-
|
SARS-CoV
|
Metabolic Disease
|
SS148 is a dual inhibitor of nsp14/nsp16 MTase. SS148 significant inhibits nsp10–nsp16 with an IC50 of 1.2 μM .
|
-
-
- HY-158322
-
|
SARS-CoV
|
Infection
|
Nsp12-IN-1 is a nucleoside analogue. Nsp12-IN-1 can block the synthesis of viral RNA and inhibit viral replication. Nsp12-IN-1 can be used in the study of pan-coronavirus .
|
-
-
- HY-150681
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC50 value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19 .
|
-
-
- HY-155679
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor of SARS-CoV-2 nsp14 methyltransferase (IC50=19 nM). SARS-CoV-2 nsp14-IN-4 is non-cytotoxic and cell-permeable. SARS-CoV-2 nsp14-IN-4 is used in COVID-19 research .
|
-
-
- HY-150625
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is agentlike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect .
|
-
-
- HY-168473
-
|
SARS-CoV
DNA/RNA Synthesis
|
Infection
|
13-TP is an inhibitor of SARS-CoV-2. 13-TP effectively inhibits the SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp82) catalyzed in vitro RNA synthesis. 13-TP completely inhibits the RdRp polymerization activity. 13-TP blocks the full extension of some of the primer RNA .
|
-
-
- HY-155983
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-4 (Compound 12q) is a selective SARS-CoV-2 nsp14 methyltransferase inhibitor with an IC50 value of 19 ± 2.5 nM. SARS-CoV-2 nsp14-IN-4 (Compound 12q) do not have a zwitterionic character and can penetrate into cells. SARS-CoV-2 nsp14-IN-4 (Compound 12q) can be used for COVID-19 and its causative agent SARS-CoV-2 research .
|
-
-
- HY-150623
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
|
-
-
- HY-150624
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
|
-
-
- HY-150626
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-5 (compound C6) is a potent SARS-CoV-2 nsp13 inhibitor with IC50 values of 50 and 55 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-5 can be used for researching anti-COVID-19 .
|
-
-
- HY-150064
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp3-IN-2 is a macrodomain (Mac1) inhibitor with IC50 value of 180 μM. SARS-CoV-2 nsp3-IN-2 is a small molecule chemical probe and can be used for the research of viral .
|
-
-
- HY-150632
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
|
-
-
- HY-149321
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 3.5 μM) .
|
-
-
- HY-150680
-
|
SARS-CoV
Histone Methyltransferase
DNA Methyltransferase
|
Infection
|
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases .
|
-
-
- HY-155280
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-60 (compound 5a) is an S-adenosylmethionine (SAM)-competitive and irreversible SARS-CoV-2 nsp16-nsp10 methyltransferase activity inhibitor with an IC50 of 9 μM and a Ki of 26 μM. SARS-CoV-2-IN-60 can specifically occupy a newly identified pocket adjacent to the SAM-binding site on nsp16. SARS-CoV-2-IN-60 has the potential for pan-coronavirus therapeutics .
|
-
-
- HY-19102
-
-
-
- HY-163614
-
-
-
- HY-168050
-
|
Virus Protease
|
Infection
|
nsP2 Protease-IN-1 is a potent irreversible covalent inhibitor of Chikungunya (CHIKV) nsP2 cysteine protease with an IC50 value of 60 nM. nsP2 Protease-IN-1 demonstrates potent antialphavirus activity, inhibiting CHIKV and VEEV replication with EC50 = 0.01 and 0.3 µM, respectively .
|
-
-
- HY-171189
-
|
SARS-CoV
|
Infection
|
C-467929 is an Nsp15 endoribonuclease inhibitor with an IC50 of 8 μM. C-467929 binds to the SARS-CoV Nsp15 protein and can be utilized in infection research .
|
-
-
- HY-108986
-
|
Sirtuin
SARS-CoV
|
Cancer
|
JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
|
-
-
- HY-156597
-
AT-752 free base
|
SARS-CoV
|
Infection
|
Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .
|
-
-
- HY-173199
-
|
Virus Protease
|
|
PRRSV-IN-1 (Compound 4s) is a nsp4 protease inhibitor targeting PRRSV, exhibiting an EC50 of 0.45 μM against PRRSV. It binds to the nsp4 protease with a Kd value of 29.24 pM and inhibits nsp4 protease activity with an IC50 of 80.36 pM. PRRSV-IN-1 can be used for research in the field of antiviral infections .
|
-
-
- HY-143467
-
|
SARS-CoV
|
Infection
|
SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14) .
|
-
-
- HY-153719
-
|
SARS-CoV
|
Infection
|
NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM .
|
-
-
- HY-W423489
-
S-Adenosyl-DL-homocysteine
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
|
-
-
- HY-144798
-
|
SARS-CoV
|
Infection
|
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .
|
-
-
- HY-D0891
-
|
Fluorescent Dye
|
Others
|
NSP-AS is chemiluminescent acridinium substrate II and can be used in homo geneous assays .
|
-
-
- HY-W024485
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-86 (Compound 2734589) is a dual inhibitor of the methyltransferases nsp14 and nsp16 of SARS-CoV-2. SARS-CoV-2-IN-86 exhibits low toxicity with a LD50 of 700 mg/kg according to toxicity analysis predict .
|
-
-
- HY-169102
-
|
Virus Protease
|
Infection
|
CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structural protein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .
|
-
-
- HY-146987
-
-
-
- HY-144799
-
-
-
- HY-N2014
-
-
-
- HY-149317
-
|
SARS-CoV
|
Infection
|
ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 20 μM) .
|
-
-
- HY-149319
-
|
SARS-CoV
|
Infection
|
ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 6 μM) .
|
-
-
- HY-149322
-
|
SARS-CoV
|
Infection
|
Z795161988 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 2.2 μM) .
|
-
-
- HY-168441
-
|
SARS-CoV
|
Infection
|
NCGC00537446 is a dual Nsp14 MTase/ExoN inhibitor. NCGC00537446 can be used for the research of SARS-CoV-2 replication and infection .
|
-
-
- HY-N14351
-
|
SARS-CoV
Bacterial
Antibiotic
|
Infection
|
Ferrocin A is a lipopeptide compound that targets the SARS-CoV-2 RNA-dependent RNA polymerase (nsp12). Ferrocin A can stably bind to nsp12, and as an iron-chelating peptide, it reduces the concentration of free iron in the environment via complexation, thereby inhibiting bacterial growth by repressing the acquisition of essential metal cations. As an iron-chelating antiviral molecule, Ferrocin A may be used in studies related to COVID-19 and bacterial infections .
|
-
-
- HY-149320
-
|
SARS-CoV
|
Infection
|
Acryl42-10 is a covalent inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 7 μM) .
|
-
-
- HY-N2014R
-
|
SARS-CoV
Amyloid-β
Ferroptosis
Tau Protein
Caspase
Bcl-2 Family
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Verbenalin (Standard) is the analytical standard of Verbenalin. This product is intended for research and analytical applications. Verbenalin is an orally active terpenoid glycoside that can be extracted from the medicinal plant Verbena officinalis. Verbenalin has anti-inflammatory, antiviral, and neuroprotective effects. Verbenalin has a strong binding affinity to the nsp-12 protein of the SARS-CoV-2 virus. Verbenalin can be used in the research of inflammatory and nervous system diseases such as hepatitis and Alzheimer's disease .
|
-
-
- HY-161762
-
|
Virus Protease
|
Infection
|
RA-0002034 is a Chikungunya virus (CHIKV) nsP2 protease inhibitor with an IC50 of 58 nM. RA-0002034 covalently modifies the catalytic cysteine in a site-specific manner .
|
-
-
- HY-161762A
-
|
Influenza Virus
|
Cancer
|
(E/Z)-RA-0002034 is a Chikungunya virus (CHIKV) nsP2 protease inhibitor with IC50 of 58 nM. RA-0002034 covalently modifies the catalytic cysteine in a site-specific manner.
|
-
-
- HY-157439
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-COV-2 papain-like protease domain that can trigger the degradation of NSP3 .
|
-
-
- HY-D0892
-
|
Biochemical Assay Reagents
|
Others
|
NSP-DMAE-NHS is an acridinium ester chemiluminescence reagent containing N-sulfopropyl group. It is useful in the clinical diagnostics industry, especially in automated immunochemistry analyzers such as the ADVIA Centaur system from Siemens Healthcare Diagnostics.
|
-
-
- HY-105721
-
|
SARS-CoV
|
Infection
|
Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research .
|
-
-
- HY-162177
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .
|
-
-
- HY-149362
-
|
SARS-CoV
|
Infection
|
MTase-IN-1 (compound 26) is a potent and selective inhibitor of coronavirus nsp14 N7-methyltransferases, with an IC50 of 0.72 nM. MTase-IN-1 impairs viral RNA translation and immune evasion .
|
-
- HY-169998
-
|
SARS-CoV
|
Infection
|
XJ5 is a non-nucleoside covalent inhibitor of Nsp12 (IC50=0.12 μM), which is the non-structural protein 12 of the virus. XJ5 has the potential to be an antiviral inhibitor of SARS-CoV-2 .
|
-
- HY-163785
-
|
SARS-CoV
|
Infection
|
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
|
-
- HY-144800
-
|
SARS-CoV
|
Infection
|
FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme .
|
-
- HY-162956
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor for SARS-CoV-2 Nsp15 endoribonuclease with an IC50 of 53.5 μM. SARS-CoV-2-IN-97 exhibits low cytotoxicity in A549-AT cell with IC50 of 134 μM .
|
-
- HY-170523
-
|
SARS-CoV
DNA Methyltransferase
|
Infection
|
RU-0415529 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 of 356 nM. RU-0415529 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and the viral replication. RU-0415529 exhibits anti-infectious activity in mouse models .
|
-
- HY-159890
-
|
SARS-CoV
|
Infection
|
MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488) .
|
-
- HY-170524
-
|
SARS-CoV
DNA Methyltransferase
|
Infection
|
TDI-015051 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 ≤0.15 nM. TDI-015051 inhibits SARS-CoV-2 NSP14 in Huh-7.5 cell (EC50=11.4 nM) and in ACE2-TMPRSS2 expressing A549 cell (EC50=64.7 nM). TDI-015051 also inhibits other coronaviruses like α-hCoV-NL63, α-hCoV-229E and β-hCoV-MERS with IC50s of 1.7, 2.6 and 3.6 nM, respectively. TDI-015051 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and viral replication, and exhibits anti-infectious activity in mouse models .
|
-
- HY-146581
-
|
Cathepsin
|
Inflammation/Immunology
|
Cathepsin C-IN-4 (compound SF27) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 65.6 nM. Cathepsin C-IN-4 also inhibits THP-1 and U937 cell, with IC50 values of 203.4 and 177.6 nM, respectively .
|
-
- HY-170649
-
|
SARS-CoV
|
Infection
|
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
|
-
- HY-146379
-
|
SARS-CoV
|
Infection
|
SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
|
-
-
-
HY-L052
-
|
1,461 compounds
|
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1,461 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
|
Cat. No. |
Product Name |
Type |
-
- HY-D0893
-
|
Fluorescent Dyes/Probes
|
NSP-SA-NHS is an acridinium ester that can be used for chemiluminescent immunoassay. A rapid and sensitive chemiluminescent immunoassay of Bisphenol A (BPA) with NSP-SA-NHS-labeled has been developed .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5416
-
|
Peptides
|
Others
|
GGASCCLYCRCH is a biological active peptide. (can inhibit the 2-O-methyltransferase activity of the SARS-CoV complex nsp16/10)
|
-
- HY-KE7008
-
|
MCE BstB I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products. Isoschizomers: Asu II, Bpu14 I, Bsp119 I, BspT104 I, Nsp V, Sfu I.
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
|
Classification |
-
- HY-163785
-
|
|
Azide
|
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: